HHH. Chih-Ho Hong

H. Chih-Ho Hong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


H. Chih-Ho Hong has a total of 167 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lebrikizumab Provides Stable and Deep Long-Term Response with No/Minimal Fluctuations up to 3 Years in Patients with Moderate-to-Severe Atopic Dermatitis

    by Linda Stein Gold, Andreas Wollenberg, Peter Lio, Jose Manuel Carrascosa, James Del Rosso, Ken Igawa, H. Chih-Ho Hong, Joseph Merola, Leon Kircik, Gaia Gallo, et al.

  • Open Access

    Real-World Evidence of Upadacitinib in Atopic Dermatitis after Inadequate Response or Intolerance to Dupilumab: The CAN UpTIMISE Study

    by Vimal H. Prajapati, Vipul Jain, Melinda J. Gooderham, Michael Cecchini, Jason K. Lee, Charles W. Lynde, Parbeer Grewal, Andrew Ferrier, David Préfontaine, Carly Sterling, et al.

  • Open Access

    Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial

    by José Manuel Carrascosa, Vimal H. Prajapati, H. Chih‐Ho Hong, Viktoria Eleftheriadou, Athanasios Tsianakas, Alexander A. Navarini, Ketty Peris, Eingun James Song, Raj Chovatiya, Sébastien Barbarot, et al.

    Background: In patients with moderate atopic dermatitis (AD), topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) often do not sufficiently control AD signs/symptoms, and escalation to systemic therapy may be required. Objectives: Report 8‐week results of ruxolitinib cream in TRuE‐AD4 (NCT06238817) in patients with moderate AD who had an inadequate response/intolerance/contraindication to TCS and TCI in the past 12 months (post‐TCS and ‐TCI). Methods: Patients aged ≥18 years with AD, an Investigator's Global Assessment (IGA) of 3, Eczema Area and Severity Index (EASI) >7, itch numerical rating scale (NRS) ≥4, 10%–20% affected body surface area and Dermatology Life Quality Index score > 10 post‐TCS and ‐TCI were randomized (2:1) to twice‐daily 1.5% ruxolitinib cream or vehicle for 8 weeks. Coprimary endpoints at Week 8 were ≥75% improvement in EASI from baseline (EASI‐75) and IGA score of 0/1 with a ≥ 2‐point improvement from baseline (IGA treatment success [TS]). Results: Of 241 randomized patients (mean age, 37.0 y; 54.4% female), mean EASI and itch NRS scores were 12.6 and 7.4, respectively, at baseline. At Week 8, significantly more patients who applied 1.5% ruxolitinib cream versus vehicle achieved IGA‐TS (61.3% vs. 13.6%; p < 0.0001) and EASI‐75 (70.0% vs. 18.5%; p < 0.0001). Significantly more patients achieved a ≥ 4‐point improvement in itch NRS (itch NRS4) at Day 2 (29.8% vs. 13.7%; p = 0.0072); improvement in current itch (no recall) was observed in 15 min after the first application. No treatment‐related adverse events were serious, and the most common adverse event occurring with ruxolitinib cream was application site acne (3.8%). Conclusions: In adults with moderate AD post‐TCS and ‐TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream significantly improved clinical signs of AD, rapidly improved itch and was well tolerated. Thus, ruxolitinib cream may represent an effective topical option before escalation to systemic therapy in patients with moderate AD.


  • Open Access

    Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary

    by Eric Simpson, Lawrence F. Eichenfield, Kim A. Papp, Seth B. Forman, Adelaide A. Hebert, Mercedes E. Gonzalez, Melinda J. Gooderham, H. Chih-Ho Hong, Vimal H. Prajapati, Emma Guttman-Yassky, et al.

  • Open Access

    Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study

    by Joel C. Joyce, H. Chih-Ho Hong, Dareen D. Siri, Darryl Toth, Howard Kallender, YuTzu Kuo, Diana Stefani-Hunyady, Kim A. Papp

    Ruxolitinib cream (1.5%) has demonstrated efficacy and safety in patients aged ≥ 2 years with mild-to-moderate atopic dermatitis. We aimed to further investigate the safety and efficacy of ruxolitinib cream in adolescents with atopic dermatitis in an open-label study. Patients aged 12-17 years with atopic dermatitis, an Investigator's Global Assessment score of 2/3, and 3-20% affected body surface area applied twice-daily 1.5% ruxolitinib cream for an 8-week continuous treatment period, followed by a 44-week long-term safety period in which ruxolitinib cream was applied twice daily as needed. Safety was the primary endpoint. Secondary endpoints included plasma trough concentrations of ruxolitinib. Affected body surface area, ≥ 75% improvement from baseline in Eczema Area and Severity Index, achievement of Investigator's Global Assessment score of 0/1, and ≥ 4-point improvement from baseline in the itch Numerical Rating Scale were exploratory endpoints. Of 103 patients, 59.2% had a baseline Investigator's Global Assessment of 3. Mean baseline body surface area and Eczema Area and Severity Index scores were 8.9% and 6.4, respectively. Over 52 weeks, 42 patients (40.8%) had treatment-emergent adverse events, most commonly upper respiratory tract infection (10.7%) and nasopharyngitis (8.7%). Three patients (2.9%) had grade ≥ 3 treatment-emergent adverse events; all were considered unrelated to treatment by the investigator. Steady-state ruxolitinib plasma concentrations during the continuous treatment period were low (geometric mean [geometric coefficient of variation], 14.2 [169] nM), consistent with the lack of observed treatment-emergent adverse events associated with systemic Janus kinase inhibition. Clinical improvements occurred during the continuous treatment period and were maintained or improved with as-needed treatment through the long-term safety period to week 52 (mean affected body surface area, 1.3%; ≥ 75% improvement from baseline in Eczema Area and Severity Index, 87.0%; Investigator's Global Assessment 0/1, 82.6%; ≥ 4-point improvement from baseline in itch Numerical Rating Scale, 41.7%). Ruxolitinib cream (1.5%) was well tolerated and efficacious with long-term as-needed use in adolescents with mild-to-moderate atopic dermatitis, consistent with safety and efficacy findings reported in previous phase III studies in adolescents and adults. Clinicaltrials.gov identifier, NCT05456529 (registered 13 July, 2022).

  • Current and Future Management of Chronic Hand Eczema in Canada: Evolving Treatment Paradigms

    by Jensen Yeung, Melinda Gooderham, H. Chih-Ho Hong, Charles Lynde, Vimal H. Prajapati

    The chronic hand eczema (CHE) management landscape is rapidly evolving with emerging evidence supporting the efficacy and safety of new treatments, some of which are not included in current guidelines. Preventive measures remain a cornerstone in the management of CHE across all etiological and morphological subtypes. The array of topical therapies for CHE is expanding with mounting evidence for newer agents that directly target the underlying pathophysiology of CHE compared to older agents that are more broadly anti-inflammatory. Phototherapy remains an effective option for CHE, but access and inconvenience remain barriers in many regions. Several advances in targeted systemic therapies for CHE have been made, with some agents approved for the treatment of moderate-to-severe atopic dermatitis exhibiting efficacy in hand and foot eczema, while other agents have evidence specifically for efficacy in CHE. With this evolving treatment landscape, an updated algorithm for the management of CHE is proposed.


  • Top Cited Papers
    Open Access

    Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND

    by Andrew Blauvelt, H. Chih-Ho Hong, Norito Katoh, Richard G. Langley, Vivian Laquer, Aleksandra Lesiak, Ketty Peris, Julien Seneschal, Juan-Francisco Silvestre, Richard B. Warren, et al.

    Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease often requiring continuous therapy. The objective with the ECZTEND trial was to assess the long-term safety and efficacy of tralokinumab treatment. Methods ECZTEND was a multicountry, open-label, 5-year extension trial conducted from September 2018 to July 2024 in patients (≥ 12 years) with moderate-to-severe AD who had received up to 1 year of tralokinumab treatment in a parent trial. Patients were eligible regardless of previous randomization (tralokinumab or placebo) or treatment response in the parent trial. The primary endpoint was the number of treatment-emergent adverse events (TEAEs) through week 268. Key secondary endpoints were Investigator’s Global Assessment (IGA) and Eczema Area and Severity Index (EASI) through week 248. Results In total, 1672 patients were enrolled (4466.2 patient-years of exposure; median 2.6 years). Overall, 68.4% of patients (n = 1143) completed the trial period they consented to; 7.1% (n = 117) discontinued owing to lack of efficacy; and 4.2% (n = 72) owing to adverse events. The TEAE incidence rate was 114.3/100 patient-years with a pattern consistent with that observed in the parent trials albeit at lower rates. The majority (> 97%) of TEAEs were nonserious and of mild or moderate severity. Most (> 80%) were assessed as not related to tralokinumab by the investigator and resolved by the end of the trial. Common TEAEs (≥ 5%) included nasopharyngitis, atopic dermatitis, coronavirus infection, upper respiratory tract infection, conjunctivitis, and headache. The proportions of patients with IGA 0/1 and EASI-75/EASI-90 increased during the first 16 weeks and then remained stable through week 248 at ≥ 50% for IGA 0/1 and EASI-90, and ≥ 80% for EASI-75. Conclusions Long-term tralokinumab treatment for up to 6 years (parent trials plus ECZTEND) in patients ≥ 12 years with moderate-to-severe AD was well tolerated and maintained long-term efficacy. A graphical abstract is available for this article. Trial Registration Clinicaltrials.gov listing: NCT03587805 (ECZTEND). Graphical Abstract


  • Open Access

    Approach to the Assessment and Management of Adult Patients With Prurigo Nodularis: A Canadian Consensus

    by H. Chih-Ho Hong, Vimal H. Prajapati, Kim A. Papp, Carolyn Jack, Gurbir Dhadwal, Elena Netchiporouk, Julien Ringuet, Irina Turchin, Mark G. Kirchhof, Kerri Purdy, et al.

    Prurigo nodularis (PN) is a chronic neuroimmune‐mediated skin disease that requires comprehensive assessment and targeted management to optimize patient care. The objective of this consensus exercise was to generate an evidence‐based overview of the diagnosis and management of patients with PN for Canadian dermatologists and other healthcare professionals. Based on a review of the current literature and guided by a steering committee of 4 Canadian experts in the management of PN, statements were developed on the topics of disease definition, pathophysiology, assessment, and treatment. A panel of 14 dermatologists and 1 allergist used an 11‐point Likert scale to vote on their belief of agreement with statements generated using a modified Delphi process. Six statements reached consensus. Reflecting the consolidated clinical opinions and experience of the expert panel, these recommendations aim to guide Canadian physicians on the diagnosis and treatment of PN.

  • Open Access

    Addressing Unmet Needs in Prurigo Nodularis: Expert Canadian Dermatology Perspectives

    by Vimal H. Prajapati, H. Chih-Ho Hong, Melinda Gooderham, Kim A. Papp

    Prurigo nodularis (PN) is a distinct chronic, inflammatory, neuroimmune‐mediated skin condition characterized by pruritic, often symmetrically distributed nodules, papules, and/or plaques. Recognition of PN as a distinct entity is complicated by the absence of a precise disease definition, uncertain epidemiologic estimates, and limited assessments of disease burden. The aim of this review is to provide a critical overview of global epidemiologic data of PN and current disease definitions. The available diagnostic criteria and assessment tools to determine disease severity for PN are examined. The psychosocial and healthcare burden of PN is also reviewed. Finally, other prevailing shortcomings in this therapeutic area are discussed, including the need for a standardized treatment algorithm for PN using currently available therapies, a greater understanding of disease pathophysiology, and the development of new targeted therapies for PN.

  • Understanding Cumulative Life Course Impairment in Canadian Patients With Psoriasis

    by Jennifer Beecker, Chih-Ho Hong, Hélène Veillette, Ron Vender, Jensen Yeung, Vinod Chandran, Christine Palmay

    Cumulative life course impairment (CLCI) is the irreversible harm resulting from the chronic burden of disease, such as psoriasis. This cumulative impact encompasses physical, psychological, social, and emotional challenges that can significantly alter the life trajectory of a patient with psoriasis. The risk of CLCI and the impact of living with psoriasis are exacerbated when the disease is inadequately managed. Even with improvements in skin symptoms, psychological factors, such as anxiety about relapse, can persist, adding to the long-term burden. The development and validation of screening tools to better identify and assess CLCI may provide a valuable framework for clinical practice, supporting holistic care and serving as an effective measure for evaluating the long-term impact of new therapies.